PrEP (Pre-Exposure Prophylaxis) refers to medication that is given to individuals at high risk of getting HIV Infections. This medicine is exclusively given to HIV negative individuals as it stops HIV from taking hold and spreading throughout the body. PrEP should be offered as an additional preventive measure/choice for HIV infection in addition to other prevention measures e.g condoms.
PHDA has been at the fore front of HIV
in 2015 facilitated by funding from Bill and Melinda Gate foundation with support from LVCT, PHDA through its SWOP project joined others global demonstration studies aimed at “Demonstrating Effective Delivery of Daily Oral HIV Pre-Exposure Prophylaxis as Part of HIV Combination Prevention Intervention Among Female Sex Workers
To validate tools for risk identification and indications for PrEP initiation among YW at high HIV risk
To document PrEP side effects and adverse events among FSW
of HIV re-testing among FSW
Develop tools, strategies and messaging to promote uptake and sustained adherence to PrEP as part of a combination prevention package.
To demonstrate effective delivery of oral HIV PrEP as part of a combined prevention package among FSWs
Outcomes or is it still ongoing??
After the successful completion of the demonstration study in July 2016, the Ministry of Health in Kenya released HIV treatment and prevention guidelines recommending
PHDA through SWOP in partnership with JPIEGO is implementing Prep scaleup among
Kenya Launches Self-test kits and PrEP